NCT04249583.

Methods	Randomised, double‐blind, placebo‐controlled, multicentre trial
Participants	300 participants Inclusion criteria Male or female 18 years of age or older Moderate to severe GL at maximum frown as assessed by the Investigator Moderate to severe GL at maximum frown as assessed by the participant Exclusion Criteria Previous use of any Botulinum toxin in facial areas within 9 months prior to study treatment Female who is pregnant, breastfeeding, or intends to conceive a child during the study Known allergy or hypersensitivity to any component of the investigational product (QM1114‐DP) or any botulinum toxin serotype Country USA
Interventions	Intervention QM1114‐DP‐ intramuscular injection into glabellar lines Comparator Placebo‐ intramuscular injection into glabella lines
Outcomes	Primary outcome Percentage of participants with a ≥ 2‐grade improvement from baseline on the Glabellar Lines Investigator and participant assessments at maximum frown at one month. [Time Frame: One Month] Secondary outcome Percentage of participants with a 0 or 1 on the Glabellar Lines Investigator scale at maximum frown [Frame: Baseline through Month 6] Number of participants who experienced an adverse event [Time Frame: Baseline through Month 6] Number of participants with abnormal post‐baseline QTcF and QTcB intervals [Time Frame: Baseline through Month 6] Number of participants with binding neutralising antibodies [Time Frame: Baseline through Month 6]
Notes	Q‐Med AB